InMed Pharmaceuticals Faces Nasdaq Minimum Bid Price Noncompliance
InMed Pharmaceuticals (INM) has received a Nasdaq notification for noncompliance with the minimum bid price requirement, as its shares traded below $1.00 for 30 consecutive days. The company has 180 days to regain compliance, with a possible 180-day extension, to avoid delisting. An analyst rates INM as a Hold with a $0.64 price target, while TipRanks' AI Analyst, Spark, rates it as Neutral due to weak financial performance and a bearish technical trend.
MAR 27·Investing News Network▼
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
InMed Pharmaceuticals Inc. (NASDAQ: INM) announced it received a notice from Nasdaq regarding its failure to meet the minimum $1.00 bid price requirement for continued listing. The company's common stock traded below this threshold for 30 consecutive trading days between February 11, 2026, and March 26, 2026. InMed has 180 calendar days to regain compliance, and its shares will continue to trade on The Nasdaq Capital Market under the symbol "INM" while it explores options to cure the deficiency.
MAR 6·GeneOnline→
InMed Pharmaceuticals Shifts Focus to Therapeutic Programs, Ends BayMedica’s Non-Pharmaceutical Cannabinoid Sales
InMed Pharmaceuticals has announced a strategic shift to prioritize its pharmaceutical development pipeline, discontinuing the commercialization of non-pharmaceutical cannabinoid products under BayMedica. This decision aims to reallocate resources towards core pharmaceutical research and development, particularly focusing on treatments for dermatological and neurological conditions using rare cannabinoids. The move reflects InMed's commitment to advancing its clinical-stage programs and optimizing operational efficiency.
